Company HedgePath Pharmaceuticals Inc
Equities
US42278K1025
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Frank O'Donnell
CEO | Chief Executive Officer | 74 | 12/12/22 |
James McNulty
DFI | Director of Finance/CFO | 73 | 12/12/22 |
Amy M. McCord
LAW | General Counsel | - | 31/12/18 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Frank O'Donnell
CEO | Chief Executive Officer | 74 | 12/12/22 |
Samuel Sears
BRD | Director/Board Member | 80 | 01/08/13 |
Ronald Osman
BRD | Director/Board Member | 78 | 22/08/23 |
Niraj Vasisht
BRD | Director/Board Member | 61 | 12/12/22 |
Michelle Yanez
BRD | Director/Board Member | 52 | 12/12/22 |
Michael Jerman
BRD | Director/Board Member | 40 | 23/05/23 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 172,323,545 | 71,550,692 ( 41.52 %) | 0 | 41.52 % |
Company contact information
Inhibitor Therapeutics, Inc.
449 South 12th Street Unit 1705
33602, Tampa
+813 864 2562
http://www.inhibitortx.com![address HedgePath Pharmaceuticals Inc](https://cdn.zonebourse.com/static/address/13988991.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+25.83% | 46.56B | |
+45.38% | 41.67B | |
+0.69% | 41.16B | |
+30.52% | 32.4B | |
+22.30% | 28.18B | |
-6.35% | 28.1B | |
+49.25% | 14.52B | |
+49.18% | 13.74B | |
+3.45% | 12.17B |